RE: All Lth’s throw £500 in the hole17 Feb 2020 20:49
SL100 - There are 485 million MTFB shares, so the current mcap is around £630K. I cannot remember all the facts and figures from 1 year + ago and our friend SP250 has generated lots of posts to trawl through so it it would take ages to search back through them. There were a few knowledgeable guys including doctors and a guy called something like IvySpivey who knew about medical trials. Taking a drug to stage 3 trials costs $100s of millions. MTFB spent this money to get Iclaprim to stage 3 with FDA. The FDA voiced their concerns about not enough tests done on liver toxicity tests, so more stage 3 trials need to conducted before there was a chance of approval. I'm not in the medical field, but I didn't think liver toxicity was that big a problem. Okay we only have 1 liver, but if the drug doesn't kill a patient (from what I remember nobody died taking it) the liver repairs itself after a recovery period. So further stage 3 trials were necessary - might take 1 year + to conduct and cost $200m but MTFB don't have enough funds.
If a big pharma comes along, drug has passed most of stage 3 - just might need to spend another $200m to ensure drug isn't overly toxic to the livers of patients. How much is a big pharma likely to pay for Iclaprim and all the current stage 1-3 research/test results that may have already cost $500m or more? I don't know, but they probably want to get it as cheap as possible!
485 million shares at 1p each would cost anybody interested in Iclaprim around £5m. So is Iclaprim and maybe $500m worth of research worth £5m, £10m, £15m or £20m? Is there anybody even interested in Iclaprim at any cost? That is the current £630K question!